News Bayer takes control of Loxo duo as Lilly closes takeover Bayer has acquired full rights to two drugs partnered with Loxo Oncology, on the same day that the biotech was taken over by Eli Lilly in an
News Lilly further boosts cancer pipeline with $8bn Loxo acquisit... In the second big M&A deal of the year following BMS’s acquisition
News Bayer/Loxo drug approved in cancers with certain mutation The FDA has approved Bayer and Loxo’s Vitrakvi (larotrectinib) for adults and children whose cancers have a specific genetic feature, or biomarker.
Views & Analysis ASCO 2018 - Tuesday 5th June: Tesaro developing checkpoint c... Breast cancer has been one area where checkpoint inhibitors have not yet gained traction – but that might be about to change following results announced by Tesaro at the American Society of
News Neuralink gets okay for its first international trial Elon Musk's brain-computer interface (BCI) company Neuralink has been given the green light to test its device in tetraplegic patients in Canada
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends